GSK buys ARDS candidate for up to £218 million
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline is to pay Apeiron Biologics £11 million up front for exclusive rights to APN01 (recombinant human Angiotensin converting enzyme 2, rhACE2), its treatment for acute respiratory distress syndrome (ARDS).